Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

Last month, the company submitted a new drug application (NDA) seeking approval for chenodiol for treating cerebrotendinous xanthomatosis (CTX) patients in the United States. The NDA filing was based on positive data from the phase III RESTORE study. Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for the treatment of CTX, a rare autosomal genetic disorder. We remind investors that in August 2023, Mirum acquired all assets of Travere Therapeutics' bile a ...